News

Iceni Planning a Phase 2 Study of Cilengitide in Multiple Myeloma Patients

Iceni Pharmaceuticals, formerly known as Big DNA Ltd., announced plans to soon begin testing its lead product Cilcane (cilengitide) as a first-in-class treatment for multiple myeloma (MM). The company, working with Merck Serono, was previously evaluating cilengitide in late-stage clinical trials as a potential treatment for glioblastoma, a brain cancer. Cilengitide is…

Amgen to Present New Data on Kyprolis, a Multiple Myeloma Treatment, at EHA 2016

Amgen announced it will present new data on its cancer portfolio at the 21st Congress of the European Hematology (EHA) Association taking place next month in Copenhagen. The data will include recent evaluations of the drugs Blincyto (blinatumomab), Kyprolis (carfilzomib), Aranesp (darbepoetin alfa) and Nplate (romiplostim) in treating a range of malignancies, such as multiple…

Ongoing Phase 3 Study Finds Daratumumab Improves Survival in Advanced Multiple Myeloma Patients

Genmab has announced positive results from its Phase 3 POLLUX study investigating the efficacy of daratumumab, in combination with lenalidomide and dexamethasone, to treat patients with relapsed or refractory multiple myeloma, compared to lenalidomide and dexamethasone alone. The ongoing trial met its primary endpoint, with treated patients demonstrating improved progression-free survival, indicating that the…